VOC Health Selected to Participate in NIH’s RADx Initiative
Partnership with University of Pennsylvania will develop and commercialize a handheld device that quickly tests for COVID-19.
VOC Health Inc. will participate in NIH’s RADx initiative to “speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing.” VOC Health was chosen by Penn, recipient of an NIH grant, to commercialize the A.T. Charlie Johnson Lab’s proprietary nanotechnology which detects volatile organic compounds (VOCs). The partnership will provide the NIH a unique approach to disease and virus detection.
“We’re pleased to have the opportunity to bring Charlie’s lab-bench device to market. As the lab continues to develop and test the technology for virus detection, we will be responsible for the systems and methods needed to make the device commercially available. That is, small, durable, easy-to operate and able to be mass produced quickly,” says Richard Postrel, CEO of VOC Health.
“We believe our nanotechnology will deliver an easy-to use, non-invasive COVID-19 test – providing results in minutes. This is the type of fast, accurate test needed to get the nation safely back to normal life,” says principal investigator Dr. A.T. Charlie Johnson, a founding member of VOC Health. “VOCs are an underused bio-marker in the medical field. Our research indicates that our successful results using VOCs to detect early-stage ovarian cancer can be applied to the detection of specific VOCs related to the COVID-19 virus, using saliva or body odor.”
Preliminary results on a small sample set have accurately detected COVID-19 from body odor with 92% sensitivity and 87% specificity.